Cargando…
Use of cell proliferation data in cancer risk assessment: FDA view.
The possible uses of cell proliferation data in cancer risk assessment can be divided into three categories: direct use of mathematical models that incorporate rates of cell proliferation, use of experimental data on secondary mechanisms produced by cell proliferation, and using studies of cellular...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1519445/ https://www.ncbi.nlm.nih.gov/pubmed/8013401 |
_version_ | 1782128654589886464 |
---|---|
author | Scheuplein, R J |
author_facet | Scheuplein, R J |
author_sort | Scheuplein, R J |
collection | PubMed |
description | The possible uses of cell proliferation data in cancer risk assessment can be divided into three categories: direct use of mathematical models that incorporate rates of cell proliferation, use of experimental data on secondary mechanisms produced by cell proliferation, and using studies of cellular growth rates to extend the dose range of bioassay data. These three approaches are briefly discussed and some indication of their potential application to cancer risk assessment is outlined. |
format | Text |
id | pubmed-1519445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1993 |
record_format | MEDLINE/PubMed |
spelling | pubmed-15194452006-07-26 Use of cell proliferation data in cancer risk assessment: FDA view. Scheuplein, R J Environ Health Perspect Research Article The possible uses of cell proliferation data in cancer risk assessment can be divided into three categories: direct use of mathematical models that incorporate rates of cell proliferation, use of experimental data on secondary mechanisms produced by cell proliferation, and using studies of cellular growth rates to extend the dose range of bioassay data. These three approaches are briefly discussed and some indication of their potential application to cancer risk assessment is outlined. 1993-12 /pmc/articles/PMC1519445/ /pubmed/8013401 Text en |
spellingShingle | Research Article Scheuplein, R J Use of cell proliferation data in cancer risk assessment: FDA view. |
title | Use of cell proliferation data in cancer risk assessment: FDA view. |
title_full | Use of cell proliferation data in cancer risk assessment: FDA view. |
title_fullStr | Use of cell proliferation data in cancer risk assessment: FDA view. |
title_full_unstemmed | Use of cell proliferation data in cancer risk assessment: FDA view. |
title_short | Use of cell proliferation data in cancer risk assessment: FDA view. |
title_sort | use of cell proliferation data in cancer risk assessment: fda view. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1519445/ https://www.ncbi.nlm.nih.gov/pubmed/8013401 |
work_keys_str_mv | AT scheupleinrj useofcellproliferationdataincancerriskassessmentfdaview |